Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: https://ow.ly/CxZt50RFBZH
Genprex, Inc.
Biotechnology
Austin, Texas 3,473 followers
Genprex is a gene therapy company focused on developing life-changing technologies for patients with cancer & diabetes.
About us
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company’s lead product candidate, REQORSA® (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both NSCLC clinical programs received a Fast Track Designation from the Food and Drug Administration. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
- Website
-
http://www.genprex.com
External link for Genprex, Inc.
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Austin, Texas
- Type
- Public Company
- Founded
- 2009
- Specialties
- immunogene cancer biotechnology
Locations
-
Primary
1601 Trinity St, Bldg B
#3.322.09
Austin, Texas 78712, US
Employees at Genprex, Inc.
Updates
-
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors: https://ow.ly/Enis50REih6
-
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner: https://ow.ly/KMOB50RzZii
-
Genprex’s compelling data presented at #AACR24 validates the potential of REQORSA and the ONCOPREX Delivery System as innovative cancer treatments. Presented poster details can be found here: https://lnkd.in/g9PPXUV6 AACR
-
Genprex recently announced we have added multiple clinical trial sites for the Acclaim-3 clinical study of Reqorsa® Immunogene Therapy in combination with Genentech’s Tecentriq® to treat patients with ES #SCLC. More details: https://ow.ly/KZSH50RtHBj
-
At #AACR24, collaborators presented positive preclinical data from studies of lead product candidate, Reqorsa® Immunogene Therapy, as well as NPRL2 #genetherapy, which both utilize our non-viral Oncoprex® Delivery System for the treatment of lung cancer. Details: https://ow.ly/fhbN50RtHrz AACR
-
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences: https://ow.ly/mbCT50RtwAm
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences - Genprex
https://www.genprex.com
-
Positive preclinical data with NPRL2 gene therapy utilizing the Oncoprex® delivery system was recently been published by our research collaborators. Learn more about the study in our latest announcement here: https://ow.ly/opOG50R9ncA $GNPX #Oncology #KRAS
-
CEO Spotlight: “These positive #preclinical data are very encouraging and support NPRL2 #genetherapy as a potential treatment for a sub-group of #NSCLC in which patients traditionally are resistant to existing therapies.” Discover more: https://ow.ly/cW4850R9n73 $GNPX #Oncology #KRAS
-
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 GeneTherapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting. Read the press release here: https://ow.ly/Aq9g50Rbqot